Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15419 ↗At a glance
Journal article in Clinical Transplantation, 2024. Written by Guy A MacGowan and 4 co-authors. Institution: Cardiothoracic Board, Freeman Hospital, Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK. Major MEDLINE topics: Heart Transplantation, Cytomegalovirus Infections, Cytomegalovirus, Antiviral Agents. Cited 1 times so far (Crossref); 10 references.
Abstract (original language)
Purpose
The aim of the study was to determine outcomes after heart transplantation for cytomegalovirus (CMV) mismatched patients (D + /R − ) who underwent a surveillance and preemptive therapy protocol, compared to nonmismatch patients.
Methods
A review of patient records from January 2010 to December 2020 with follow‐up to October 2023 was done. The protocol consisted weekly surveillance with CMV PCR starting 4 weeks after transplant continuing up until the patient seroconverts or up to 3 months posttransplant if the patient does not seroconvert. Valganciclovir was given for 2 weeks to those who seroconverted.
Results
Two hundred and twenty‐one patients were included, and 23% were mismatched patients. Overall survival was not different between CMV groups ( p = NS). Causes of death and morbidities were also not significantly different ( p = NS). Sixty‐six percent of mismatch patients seroconverted, and there was also a significantly older donor age in the seroconverted patients compared to nonseroconverted patients (41 ± 11 vs. 29 ± 12 years, p < 0.005), indicating a higher risk donor profile. A multivariate Cox regression including donor age showed that there was no increase in mortality in the seroconverted mismatches compared to nonmismatch patients ( p = NS).
Conclusions
There is no significant increased mortality or morbidity using a CMV surveillance and preemptive therapy protocol. The effect of donor age on seroconversion of mismatches requires further validation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cardiothoracic Board, Freeman Hospital, Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK.
- Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
- Department of Microbiology, Freeman Hospital, Newcastle upon Tyne Hospital Trust, Newcastle upon Tyne, UK.
ORCID profiles: Guy A MacGowan, Oscar Gonzalez-Fernandez
Cite
APA
MacGowan, G. A., Samuel, J., McDiarmid, A., Gonzalez-Fernandez, O., & Parry, G. (2024). Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy. Clinical Transplantation. https://doi.org/10.1111/ctr.15419
Vancouver
MacGowan GA, Samuel J, McDiarmid A, Gonzalez-Fernandez O, Parry G. Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy. Clinical Transplantation. 2024. doi:10.1111/ctr.15419
BibTeX
@article{MacGowan2024,
author = {MacGowan, Guy A and Samuel, Julie and McDiarmid, Adam and Gonzalez-Fernandez, Oscar and Parry, Gareth},
title = {Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15419}
}
EUVIMED